Drug, delivery and devices for diabetic retinopathy (3Ds in DR)

Expert Opinion on Drug Delivery

Volumn 13, Issue 11, 2016, Pages 1625-1637

  Nirmal, Jayabalan ^a   Radhakrishnan, Krishna ^a   Moreno, Miguel ^a   Natarajan, Jayaganesh V ^a   Laude, Augustinus ^b   Lim, Tock Han ^b,c   Venkatraman, Subbu ^a   Agrawal, Rupesh ^b,c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

anti VEGF; delivery devices; delivery systems; Diabetic retinopathy; drugs

Indexed keywords

ANTIDIABETIC AGENT; CYCLODEXTRIN; LIPOSOME; VASCULOTROPIN;

DIABETIC RETINOPATHY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; EMULSION; HUMAN; HYDROGEL; IMPLANT; INFLAMMATION; MICELLE; PARTICULATE MATTER; PATHOPHYSIOLOGY; POLYMERIZATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING; BLOOD RETINA BARRIER; METABOLISM;

BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84991383517     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1188800     Document Type: Review

References (124)

1. L.M.Aiello Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003 Jul;136(1):122–135.
2. I.Klaassen, C.J.Van Noorden, R.O.Schlingemann Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013 May;34:19–48.•• The indepth review on the cellular and molecular mechanisms about the BRB breakdown in DME and DR.
3. T.A.Ciulla, A.G.Amador, B.Zinman. Diabetic retinopathy and diabetic macular edema:pathophysiology, screening, and novel therapies. Diabetes Care. 2003 Sep;26(9):2653–2664.• This article covered the various aspects of pathophysiolgy involved in DR and DME. Also readers are encouraged to read to know about the other possible mechanisms involved in DR which are not covered in our article.
4. T.S.Kern. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
5. C.H.Meyer. Current treatment approaches in diabetic macular edema. Ophthalmologica. 2007;221(2):118–131.
6. G.Villar, Y.Garcia, I.Goicolea, et al. Determinants of development of microalbuminuria in normotensive patients with type 1 and type 2 diabetes. Diabetes Metab. 1999 Sep;25(3):246–254.
7. P.D.Reaven, N.Emanuele, T.Moritz, et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2008 May;31(5):952–957.
8. M.E.Kleinman, J.Z.Baffi, J.Ambati. The multifactorial nature of retinal vascular disease. Ophthalmologica. 2010;224 Suppl 1:16–24.
9. R.J.Antcliff, J.Marshall. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999 Dec;14(4):223–232.
10. M.Dahrouj, D.M.Desjardins, Y.Liu, et al. Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure. Exp Eye Res. 2015;137:50–56.
11. N.Miyamoto, Y.De Kozak, J.C.Jeanny, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown:potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2007;50:461–470.
12. N.Shams, T.Ianchulev. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006 Sep;19(3):335–344.
13. M.J.Tolentino, J.W.Miller, E.S.Gragoudas, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996 Nov;103(11):1820–1828.
14. H.Funatsu, H.Yamashita, H.Noma, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002 Jan;133(1):70–77.
15. L.P.Aiello, R.L.Avery, P.G.Arrigg, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480–1487.
16. P.A.Campochiaro. Retinal and choroidal neovascularization. J Cell Physiol. 2000 Sep;184(3):301–310.
17. E.Dejana, R.Spagnuolo, G.Bazzoni. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb Haemost. 2001 Jul;86(1):308–315.
18. J.Tang, T.S.Kern. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011 Sep;30(5):343–358.•• This review article contains a deep insight about the role of inflammation in DR.
19. A.Russo, C.Costagliola, L.Delcassi, et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm. 2013;2013:476525.
20. E.Rechtman, A.Harris, H.J.Garzozi, et al. Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clin Ophthalmol. 2007 Dec;1(4):383–391.
21. R.Singh, K.Ramasamy, C.Abraham, et al. Diabetic retinopathy:an update. Indian J Ophthalmol. 2008 May-Jun;56(3):178–188.
22. A.Urtti. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1131–1135.• The articles provide an idea about different commonly used routes of ocular therapeutics and the challenges of ocular pharmacokinetics.
23. P.M.Hughes, O.Olejnik, J.E.Chang-Lin, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005 Dec 13;57(14):2010–2032.•• The review covers the various ocular barriers for drug delivery to posterior segment and about the different drug transport mechanisms in the eye.
24. T.S.Kern, C.M.Miller, Y.Du, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007 Feb;56(2):373–379.
25. M.Shimura, K.Yasuda. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol. 2015 Feb;99(2):215–219.
26. A.Klettner, J.Roider. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro:efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523–4527.
27. J.J.Chen, S.E.Ebmeier, W.M.Sutherland, et al. Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye (Lond). 2011 Nov;25(11):1504–1511.
28. F.Bandello, C.Preziosa, G.Querques, et al. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52(2):89–96.• The article covered the updates about the clinical trial results of intravitreal steroid implants for DME.
29. V.P.Ranta, A.Urtti. Transscleral drug delivery to the posterior eye:prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164–1181.
30. H.Nomoto, F.Shiraga, N.Kuno, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4807–4813.• This study demostrated the evidence about the possibility of subconjunctival anti-VEGF agent (bevacizumab) to reach retina.
31. Y.Zhao, W.Lei. [Retina penetration of subconjunctival ranibizumab injection in the rabbit eye]. Zhonghua Yan Ke Za Zhi. 2015 May;51(5):356–359.
32. N.Ferrara, L.Damico, N.Shams, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859–870.
33. L.Shen, J.Mao, Y.Chen, et al. Transscleral permeation of subtenon triamcinolone in different vitreoretinal diseases. Ophthalmology. 2015 Mar;122(3):649–651.
34. M.Paul, V.Vieillard, E.Roumi, et al. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Ann Pharm Fr. 2012 May;70(3):139–154.
35. L.Signorello, S.Pucciarelli, G.Bonacucina, et al. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions. Curr Pharm Biotechnol. 2014;15(2):113–119.
36. N.A.Yannuzzi, M.A.Klufas, L.Quach, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015 Jan;133(1):32–39.
37. Y.Wang, D.Fei, M.Vanderlaan, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–345.
38. Q.D.Nguyen, D.M.Brown, D.M.Marcus, et al. Ranibizumab for diabetic macular edema:results from 2 phase III randomized trials:RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789–801.
39. D.V.Do, U.Schmidt-Erfurth, V.H.Gonzalez, et al. The DA VINCI Study:phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology. 2011 Sep;118(9):1819–1826.
40. U.H.Weidle, B.Schneider, G.Georges, et al. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics. 2012 Nov;9(6):357–372.
41. C.T.A.Struble, M.Gerometta, M.Kreuger, et al. Ocular distribution and pharmacokinetics of 125I-OPT302 and 125I-Aflibercept (EYLEA) following intravitreal administration to pigmented rabbits. Acta Ophthalmologica. 2014;92(s253).
42. R.F.Gariano, T.W.Gardner. Retinal angiogenesis in development and disease. Nature. 2005 Dec 15;438(7070):960–966.
43. T.S.Kern, R.L.Engerman. Pharmacological inhibition of diabetic retinopathy:aminoguanidine and aspirin. Diabetes. 2001 Jul;50(7):1636–1642.
44. A.Stitt, T.A.Gardiner, N.L.Alderson, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826–2832.
45. D.W.Dawson, O.V.Volpert, P.Gillis, et al. Pigment epithelium-derived factor:a potent inhibitor of angiogenesis. Science. 1999 Jul 9;285(5425):245–248.
46. A.Bhatwadekar, J.V.Glenn, J.L.Figarola, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol. 2008 Apr;92(4):545–547.
47. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol. 1990 Sep;108(9):1234–1244.
48. W.Sun, P.J.Oates, J.B.Coutcher, et al. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006 Oct;55(10):2757–2762.
49. M.I.Galvez. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review. Curr Diabetes Rev. 2009 Feb;5(1):14–17.
50. P.A.Campochiaro, C.P.S.Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004 Mar;45(3):922–931.
51. N.Gupta, S.Mansoor, A.Sharma, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10.
52. Writing Committee for the Diabetic Retinopathy Clinical, N.Research, J.G.Gross, A.R.Glassman, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy:a randomized clinical trial. JAMA. 2015 Nov 24;314(20):2137–2146.
53. N.Papadopoulos, J.Martin, Q.Ruan, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun;15(2):171–185.
54. Diabetic Retinopathy Clinical Research N, J.A.Wells, A.R.Glassman, A.R.Ayala, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 Mar 26;372(13):1193–1203.
55. NCT02194634. Safety and efficacy study of conbercept in diabetic macular edema (DME) (sailing). [cited 2015 Dec 1]. Available from:https://clinicaltrials.gov/ct2/show/NCT02194634.
56. Z.Wu, P.Zhou, X.Li, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS One. 2013;8(3):e57642.
57. C.Struble, A.Tester, M.Gerometta, et al. Ocular distribution and pharmacokinetics of 125I-OPT302 and 125I-Aflibercept (EYLEA) following intravitreal administration to pigmented rabbits. Acta Ophthalmologica. 2014;92:0–0.
58. A.Stahl, M.T.Stumpp, A.Schlegel, et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis. 2013 Jan;16(1):101–111.
59. H.K.Binz, P.Amstutz, A.Kohl, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol. 2004 May;22(5):575–582.
60. W.Yu, Y.Bai, N.Han, et al. Inhibition of pathological retinal neovascularization by semaphorin 3A. Mol Vis. 2013;19:1397–1405.
61. A.Eichmann, F.Le Noble, M.Autiero, et al. Guidance of vascular and neural network formation. Curr Opin Neurobiol. 2005 Feb;15(1):108–115.
62. M.Melani, B.M.Weinstein. Common factors regulating patterning of the nervous and vascular systems. Annu Rev Cell Dev Biol. 2010;26:639–665.
63. N.K.Agrawal, S.Kant. Targeting inflammation in diabetes:newer therapeutic options. World J Diabetes. 2014 Oct 15;5(5):697–710.
64. V.S.Dedania, S.J.Bakri. Novel pharmacotherapies in diabetic retinopathy. Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):164–173.
65. M.Nauck, M.Roth, M.Tamm, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997 Apr;16(4):398–406.
66. M.Nauck, G.Karakiulakis, A.P.Perruchoud, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998 Jan 12;341(2–3):309–315.
67. S.G.Schwartz, H.W.FlynnJr., I.U.Scott. Emerging drugs for diabetic macular edema. Expert Opin Emerg Drugs. 2014 Sep;19(3):397–405.
68. Diabetic Retinopathy Clinical Research N, R.W.Beck, A.R.Edwards, L.P.Aeillo, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009 Mar;127(3):245–251.
69. F.Audren, A.Erginay, B.Haouchine, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema:6-month results of a prospective controlled trial. Acta Ophthalmol Scand. 2006 Oct;84(5):624–630.
70. P.Massin, F.Audren, B.Haouchine, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema:preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218–224; discussion 224–215.
71. F.K.Sutter, J.M.Simpson, M.C.Gillies. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment:three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004 Nov;111(11):2044–2049.
72. Diabetic Retinopathy Clinical Research Network, J.Googe, A.J.Brucker, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011 Jun;31(6):1009–1027.
73. J.V.Aukunuru, G.Sunkara, S.P.Ayalasomayajula, et al. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar;19(3):278–285.
74. X.Xu, Y.Weng, L.Xu, et al. Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol. 2013;60:272–276.
75. J.A.Cardillo, A.A.Souza-Filho, A.G.Oliveira. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch Soc Esp Oftalmol. 2006 Dec;81(12):675–677, 679–681.
76. C.K.Pan, C.Durairaj, U.B.Kompella, et al. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun;27(3):219–224.
77. F.Li, B.Hurley, Y.Liu, et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J. 2012;6:54–58.
78. R.Varshochian, M.Jeddi-Tehrani, A.R.Mahmoudi, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci. 2013 Nov 20;50(3–4):341–352.
79. M.Ryu, T.Nakazawa, T.Akagi, et al. Suppression of phagocytic cells in retinal disorders using amphiphilic poly(γ-glutamic acid) nanoparticles containing dexamethasone. J Control Release. 2011 Apr 10;151(1):65–73.
80. M.Tanito, K.Hara, Y.Takai, et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(11):7944–7948.
81. G.Jóhannesson, M.D.Moya-Ortega, G.M.Ásgrímsdóttir, et al. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. Acta Ophthalmol. 2014 Sep;92(6):550–556.
82. A.Ohira, K.Hara, G.Johannesson, et al. Topical dexamethasone gamma-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. Acta Ophthalmol. 2015 Nov;93(7):610–615.
83. NCT01523314. Topical dexamethasone - cyclodextrin microparticle eye drops for diabetic macular edema. [cited 2015 Dec 1]. Available from:https://clinicaltrials.gov/ct2/results?term=NCT01523314&Search=Search.
84. S.K.Gupta, T.Velpandian, N.Dhingra, et al. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther. 2000 Dec;16(6):511–518.
85. M.Abrishami, S.Zarei-Ghanavati, D.Soroush, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 2009 May;29(5):699–703.
86. B.M.Davis, E.M.Normando, L.Guo, et al. Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small. 2014 Apr 24;10(8):1575–1584.• An interesting study demonstrated the capability of liposomes decorated with annexin could be a cargo to transport even a macromolecules like bevascizumab to back of the eye even after topical administration.
87. N.Kuno, S.Fujii. Recent advances in ocular drug delivery systems. Polymers. 2011;3(4):193–221.
88. P.Daull, C.A.Paterson, B.D.Kuppermann, et al. A preliminary evaluation of dexamethasone palmitate emulsion:a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013 Mar;29(2):258–269.
89. C.Civiale, M.Licciardi, G.Cavallaro, et al. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm. 2009 Aug 13;378(1–2):177–186.
90. I.Pepić, A.Hafner, J.Lovrić, et al. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. J Pharm Sci. 2010 Oct;99(10):4317–4325.
91. F.Rafie, Y.Javadzadeh, A.R.Javadzadeh, et al. In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye. Curr Eye Res. 2010 Dec;35(12):1081–1089.
92. Y.Yu, C.Ying. Development of injectable hydrogel based on catalyst-free click chemistry for controlled release of macromolecules - a formulation study for Avastin. ARVO annual meeting abstract. Invest Ophthalmol Vis Sci. 2014;55:474.
93. J.J.Kang Derwent, W.F.Mieler. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc. 2008;106:206–213; discussion 213–204.
94. C.H.Wang, Y.S.Hwang, P.R.Chiang, et al. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules. 2012 Jan 9;13(1):40–48.
95. P.Tyagi, M.Barros, J.W.Stansbury, et al. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013 Aug 5;10(8):2858–2867.
96. J.Xu, Y.Wang, Y.Li, et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther. 2007 Dec;23(6):527–540.
97. S.H.Boddu, J.Jwala, R.Vaishya, et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J Ocul Pharmacol Ther. 2010;26 (1):37–48.
98. T.Loftsson, D.Hreinsdóttir, E.Stefánsson. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye:aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007 May;59(5):629–635.
99. J.M.Ruiz-Moreno, J.A.Montero, L.Arias, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmol Scand. 2006 Dec;84(6):743–748.
100. A.Bochot, E.Fattal. Liposomes for intravitreal drug delivery:a state of the art. J Control Release. 2012 Jul 20;161(2):628–634.•• Very interesting review which covered detailed aspects and good perspective about the role of liposomes in intravitreal drug delivery.
101. T.Yilmaz, M.Cordero-Coma, A.J.Lavaque, et al. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy. Curr Pharm Biotechnol. 2011 Mar 1;12(3):337–346.
102. P.A.Campochiaro, G.Hafiz, S.M.Shah, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2011 Jul;117(7):1393–1399e1393.
103. Iluvien Approval History. 2014 [cited 2015 Nov30]. Available from:http://www.drugs.com/history/iluvien.html.
104. NCT00692614. A study of MK0140 in diabetic patients with macular edema (0140-001) a study of MK0140 in diabetic patients with macular edema (0140-001). [cited 2015 Dec 1]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00692614&Search=Search.
105. Ozurdex approval history. 2014 [cited 2015 Nov30]. Available from:http://www.drugs.com/history/ozurdex.html.
106. NCT01175395. 20089 TA+lucentis combo intravitreal injections for treatment of neovascular age-related macular degeneration (AMD) (20089/Combo). Available from:https://clinicaltrials.gov/ct2/show/NCT01175395?term=NCT01175395&rank=1.
107. H.Chen. Recent developments in ocular drug delivery. J Drug Target. 2015 Aug;23(7–8):597–604.
108. R.L.Avery, S.Saati, M.Journey, et al. A novel implantable, refillable pump for intraocular drug delivery. ARVO annual meeting abstract. Invest Ophthalmol Vis Sci. 2010;51:3799.
109. Dalton M. Drug-delivery micropump for chronic retina disorders. 2014 [cited 2015 Dec2]. Available from:http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/drug-delivery-micropump-chronic-retina-disorders?page=full.
110. RUBIO RG. Good early results seen with anti-VEGF refillable port delivery system. Genentech. 2013 [cited 2015 Dec4]. Available from:http://www.healio.com/ophthalmology/retina-vitreous/news/print/osn-retina/%7B4df622f8-54f7-4895-a182-a1fbbe6902b4%7D/good-early-results-seen-with-anti-vegf-refillable-port-delivery-system.
111. NCT02510794. Study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in participants with subfoveal neovascular age-related macular degeneration (LADDER). [cited 2016 Mar 31]. Available from:https://clinicaltrials.gov/ct2/show/NCT02510794?term=NCT02510794&rank=1.
112. S.S.Shah, L.V.Denham, J.R.Elison, et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol. 2010 Feb 1;5(1):75–93.•• A detailed review discussed about the major drug delivery systems and devices for the posterior segment of the eye.
113. R.N.Khurana. How to manage a migrating dexamethasone intravitreal implant review of ophthalmology. 2015 [cited 2016 Mar31]. Available from:http://www.retina-specialist.com/article/how-to-manage-a-migrating-dexamethasone-intravitreal-implant.
114. Implantation and Removal Procedures. Retinal physician. 2011 [cited 2016 Mar31]. Available from:http://www.retinalphysician.com/articleviewer.aspx?articleID=105433.
115. N.Haghjou, M.Soheilian, M.J.Abdekhodaie. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011 Oct;6(4):317–329.
116. F.E.Kane, J.Burdan, A.Cutino, et al. Iluvien:a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008 Sep;5(9):1039–1046.
117. P.A.Campochiaro, D.M.Brown, A.Pearson, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):626–635e622.
118. P.A.Campochiaro, D.M.Brown, A.Pearson, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct;119(10):2125–2132.
119. P.A.Pearson, T.L.Comstock, M.Ip, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema:a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011 Aug;118(8):1580–1587.
120. U.B.Kompella, R.S.Kadam, V.H.Lee. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010 Sep;1(3):435–456.
121. P.U.Dugel, F.Bandello, A.Loewenstein. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol. 2015;9:1321–1335.
122. D.S.Boyer, Y.H.Yoon, R.BelfortJr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–1914.
123. S.Kim, J.H.Kim, O.Jeon, et al. Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm. 2009 Mar;71(3):420–430.
124. Y.M.Kim, J.O.Lim, H.K.Kim, et al. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur J Pharm Biopharm. 2008 Sep;70(1):179–186.